A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Raloxifene (Evista)

Raloxifene hydrochloride is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in po....

First FDA approval1998-01-06
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$48.7M in CY2024 Part D spend1.1M claims · 322K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.248/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.248
Across all dosage forms in distribution.
Highest NADAC
$0.248
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Raloxifene used for?

Raloxifene hydrochloride is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in po....

Is there a generic for Raloxifene?

Yes. 8 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Raloxifene?

Across 329 Part D plans, Raloxifene averages $0.248/unit (NADAC). Lowest available: $0.248/unit. Highest in distribution: $0.248/unit.

Is Raloxifene on the FDA shortage list?

No. Raloxifene is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Estrogen Agonist/Antagonist3 alternatives in D1
01
Clomiphene
Brand: CLOMID
$6.64Lowest NADAC
6Generic mfrs
$1.4MCY24 Part D spend
Compare →
02
Ospemifene
Brand: Osphena
$8.16Lowest NADAC
0Generic mfrs
$11.4MCY24 Part D spend
Compare →
03
Tamoxifen
Brand: SOLTAMOX
$0.139Lowest NADAC
5Generic mfrs
$16.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (9 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.